A Comprehensive Guide to How Cannabinoids Interact with Drugs for Epilepsy, Cancer, Pain, and More

As medical cannabis use expands, patients are increasingly combining cannabinoids with prescription medications for serious conditions. This review maps out the drug interaction landscape across five major therapeutic areas where cannabinoid use is common: epilepsy, autism spectrum disorder, cancer, multiple sclerosis, and chronic pain.

The interactions work through several mechanisms. The most common is inhibition of cytochrome P450 (CYP) enzymes, the liver's main drug-processing system. Both THC and CBD inhibit CYP2C9 and CYP3A4 — two enzymes that collectively metabolize a large proportion of prescription drugs. When these enzymes are inhibited, co-administered medications accumulate to higher blood levels, potentially causing toxicity.

Specific examples highlight the clinical significance. The antifungal ketoconazole (a CYP3A4 inhibitor itself) increases plasma concentrations of both THC and CBD when taken together. Conversely, rifampicin (a CYP3A4 inducer, used for tuberculosis) reduces THC levels by 20-40% and CBD levels by 50-60%, potentially making cannabis treatment ineffective.

For epilepsy patients on clobazam — one of the most common co-prescribed drugs with CBD — the interaction is particularly important: CBD inhibits CYP2C19, causing clobazam levels to rise significantly, which can increase sedation and requires dose adjustment. In cancer treatment, cannabinoid interactions with chemotherapy agents could either reduce efficacy or increase toxicity.

The review emphasizes that interactions can be additive, synergistic, or antagonistic — and may affect absorption, distribution, metabolism, and excretion. The bottom line: cannabinoids are pharmacologically active drugs that interact with the body's drug processing systems in clinically meaningful ways.